Skip to main content
Clinical Trials/JPRN-UMIN000022104
JPRN-UMIN000022104
Completed
未知

Relevance of fecal calprotectin as a biomarker to predict the outcome of Adalimumab therapy in Ulcerative Colitis patients. - Relevance of fecal calprotectin as a biomarker to predict the outcome of Adalimumab therapy in Ulcerative Colitis patients.

Hyogo College of Medicine, Department of Inflammatory Bowel Disease, Division of Internal Medicine0 sites54 target enrollmentApril 27, 2016

Overview

Phase
未知
Intervention
Not specified
Conditions
lcerative Colitis
Sponsor
Hyogo College of Medicine, Department of Inflammatory Bowel Disease, Division of Internal Medicine
Enrollment
54
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
April 27, 2016
End Date
TBD
Last Updated
2 years ago
Study Type
Observational
Sex
All

Investigators

Sponsor
Hyogo College of Medicine, Department of Inflammatory Bowel Disease, Division of Internal Medicine

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • 1\. Pregnant woman \*Patients who become pregnant during study period to be required to discontinue the study 2\. Patients unable to provide informed consent.

Outcomes

Primary Outcomes

Not specified

Similar Trials